DeepMed Research

Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Phase 2

Terminated

Conditions: Prostate Cancer Metastatic
Prostate Cancer

Interventions: Other: Placebo
Drug: ODM-201

First Posted Date: 2016-10-14

Last Posted Date: 2024-03-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 92

Registration Number: NCT02933801

Locations: 🇨🇭
Hôpital du Valais (Sion et Martigny), Sion, Switzerland
🇫🇷
Centre Eugène Marquis, Rennes, France
🇮🇹
Istituto Nazionale dei Tumori - IRCCS Fondazione Pascale S.C., Napoli, Italy

and more 29 locations

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer

Phase 1

Terminated

Conditions: Rectal Cancer

Interventions: Drug: Regorafenib
Drug: Capecitabine
Radiation: Radiotherapy
Procedure: Surgery

First Posted Date: 2016-09-22

Last Posted Date: 2023-01-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 25

Registration Number: NCT02910843

Locations: 🇨🇭
St. Claraspital Basel, Basel, Switzerland
🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Inselspital Bern, Bern, Switzerland

and more 4 locations

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Phase 1

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Venetoclax

First Posted Date: 2016-08-24

Last Posted Date: 2022-06-10

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 25

Registration Number: NCT02877550

Locations: 🇨🇭
Inselspital, Bern, Bern, Switzerland
🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇨🇭
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland

and more 3 locations

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: anti-EGFR-IL-dox

First Posted Date: 2016-07-14

Last Posted Date: 2021-09-29

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 48

Registration Number: NCT02833766

Locations: 🇨🇭
Kantonsspital Graubuenden, Chur, Switzerland
🇨🇭
Universitätsspital Zürich, Zürich, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 12 locations

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Phase 2

Terminated

Conditions: Cancer of the Prostate
Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Metformin

First Posted Date: 2015-12-29

Last Posted Date: 2023-06-27

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 169

Registration Number: NCT02640534

Locations: 🇨🇭
Hôpital du Valais, Sion, Switzerland
🇨🇭
UniversitätsSpital Zürich, Zürich, Switzerland
🇨🇭
Spital Thurgau AG, Frauenfeld, Switzerland

and more 12 locations

Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy

Not Applicable

Terminated

Conditions: Metastatic Colorectal Cancer

Interventions: Other: standard therapy
Other: standard therapy + physical activity program

First Posted Date: 2015-11-04

Last Posted Date: 2022-11-07

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 100

Registration Number: NCT02597075

Locations: 🇦🇹
Universitätsklinikum der PMU Salzburg, Salzburg, Austria
🇨🇭
Tumor Zentrum Aarau, Aarau, Switzerland
🇨🇭
Clinical Cancer Research Center at University Hospital Basel, Basel, Switzerland

and more 21 locations

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: NSCLC Non-small Cell Lung Cancer

Interventions: Drug: MEDI4736 (anti-PD-L1)

First Posted Date: 2015-10-09

Last Posted Date: 2024-04-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 68

Registration Number: NCT02572843

Locations: 🇨🇭
Klinik Hirslanden Onkozentrum Zürich, Zurich, Switzerland
🇨🇭
IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Regionalspital, Thun, Switzerland

and more 16 locations

Adjuvant Aspirin Treatment for Colon Cancer Patients

Phase 3

Terminated

Conditions: Colon Cancer

Interventions: Drug: Placebo
Drug: Aspirin

First Posted Date: 2015-06-10

Last Posted Date: 2025-05-16

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 1040

Registration Number: NCT02467582

Locations: 🇩🇪
Klinikum Nuernberg, Nuernberg, Germany
🇩🇪
Pi.Tri-Studien GmbH, Offenburg, Germany
🇩🇪
CaritasKlinikum Saarbrücken, Saarbrücken, Germany

and more 57 locations

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Phase 2

Terminated

Conditions: Follicular Lymphoma

Interventions: Drug: Ibrutinib
Drug: Rituximab

First Posted Date: 2015-05-21

Last Posted Date: 2024-03-13

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 190

Registration Number: NCT02451111

Locations: 🇦🇹
Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, Austria
🇩🇰
Aalborg Universitetshospital, Aalborg, Denmark
🇫🇮
Helsinki University Hospital, Helsinki, Finland

and more 38 locations

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Adenocarcinoma

Interventions: Drug: Eribulin mesilate

First Posted Date: 2015-03-31

Last Posted Date: 2021-09-29

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 78

Registration Number: NCT02404506

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Spitalzentrum Biel, Biel, Switzerland
🇨🇭
Clinique de Genolier, Genolier, Switzerland

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy